11:49 EDT FDA panel votes 6-3 to reject AstraZeneca (AZN) breast cancer drug, Bloomberg says
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca upgraded to Buy from Hold at DZ Bank
- AstraZeneca reports Q1 core EPS $2.58, consensus $1.27
- AstraZeneca sees FY26 core EPS up low double-digit percentage
- AstraZeneca posts strong Q1 2026 growth and doubles down on high-value pipeline
- FDA Recruits AstraZeneca, Amgen in Bet on AI to Accelerate Drug Development